Motpoly Xr Capsule, Extended Release
NDC Package 73289-0063-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Motpoly Xr (lacosamide) capsules is lacosamide is used to prevent and control seizures. This formulation utilizes a capsule, extended release delivery system. Marketed by Aucta Pharmaceuticals, Inc., this product is identified by NDC 73289-0063 and is authorized under FDA application NDA216185.

Identification & Billing

NDC Package Code
73289-0063-2
Package Description
60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
Product Code
73289-0063
11-Digit Billing Format
73289006302
RxNorm Crosswalk
  • RxCUI: 2637018 - lacosamide 100 MG 24HR Extended Release Oral Capsule
  • RxCUI: 2637018 - 24 HR lacosamide 100 MG Extended Release Oral Capsule
  • RxCUI: 2637025 - Motpoly XR 100 MG 24HR Extended Release Oral Capsule
  • RxCUI: 2637025 - 24 HR lacosamide 100 MG Extended Release Oral Capsule [Motpoly]
  • RxCUI: 2637025 - 24 HR Motpoly 100 MG Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Motpoly Xr
Non-Proprietary Name
Lacosamide
Substance Name
Lacosamide
Dosage Form
Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LACOSAMIDE 100 mg/1
Pharmacologic Class
Decreased Central Nervous System Disorganized Electrical Activity - [PE] (Physiologic Effect)
Usage Information
Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.
DEA Schedule
Schedule V (CV) Substances

Regulatory & Marketing

Labeler Name
Aucta Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA216185
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-05-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (73289-0063). Click a package code to view its specific billing and regulatory data.

73289-0063-1
1 BLISTER PACK in 1 CARTON / 14 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73289-0063-2 identifies a specific commercial package of 60 capsule, extended release in 1 bottle, plastic of Motpoly Xr, a human prescription drug labeled by Aucta Pharmaceuticals, Inc.. This capsule, extended release is formulated for oral use and contains lacosamide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aucta Pharmaceuticals, Inc. on May 05, 2023. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

How is this Aucta Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73289006302. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
73289-0063-2
11-Digit CMS (5-4-2)
73289-0063-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.